The effects of drugs that treat Alzheimer’s, cancer and other illnesses are often limited by the blood-brain barrier. A small study suggests a way forward.
Analysts say the 2024 adjustment, which helps older Americans keep up with inflation, won’t be nearly as high as this year’s but will still be significant.
The drug, Leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. Still, data suggests it is more promising than the small number of other available treatments.
The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”